Expert RA upgraded PROMOMED DM's credit rating to ruA
20.05.2026
Corporate
For investors
20.05.2026
May 20, 2026, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the Group's operating results for the 1st quarter of 2026.
KEY INDICATORS
- In Q1 2026, the Group's revenue reached RUB 7.3 billion, an increase of 62.2% YoY, which is more than 5 times the growth rate of the pharmaceutical market in monetary terms (12% according to IQVIA).
- The share of commercial sales was 77%, budget sales — 23%. This sales structure is driven by the outpacing dynamics of the strategic Endocrinology segment and the Other Drugs segment.
- The share of innovative drugs in the Group's revenue was 82%, while biotechnological drugs accounted for 77%, reflecting the consistent implementation of the Group's strategy to bring high–tech modern drugs to the market.
- The Endocrinology segment has the largest sales growth, by 196% YoY, to 4.8 billion rubles. against the background of strengthening the leadership of PROMOMED blockbuster drugs for the treatment of diabetes and obesity: Tirzetta®, Velgia®, Velgia® Eco and Semaltara®.
- In the Oncology segment, according to the results of Q1 2026, sales amounted to 0.7 billion rubles. The decrease compared to the same period in 2025 is due to a change in the plan of primary shipments to suppliers that are tied to the timing of public procurement: in 2026, the key tenders for the company are concentrated in the second half of the year. The Group also expects new drug launches in the second half of 2026 and a corresponding acceleration of sales in the Budget segment.
- Growth in the Other Drugs segment was 8.7%, driven by strong sales of General Therapy drugs, Antibiotics, and Antivirals. At the same time, the relevant market grew by 3.5% to 61 billion rubles.
- According to the DSM Group agency, PROMOMED demonstrates the best sales dynamics among the leading manufacturers of the commercial market (+189%).
|
The indicator also showed during the reporting period |
1st quarter of 2026 |
1st quarter 2025 |
y/y |
|
Revenue, billion rubles, including segments: |
7,3 |
4,5 |
62,2% |
|
Endocrinology |
4,8 |
1,6 |
196% |
|
Oncology |
0,7 |
1,2 |
-45% |
|
Other drugs |
1,8 |
1,7 |
8,7% |
|
LP market, billion rubles, including segments: |
635 |
566 |
12% |
|
relevant Endocrinology market (9 INN) |
20,2 |
8,3 |
143% |
|
relevant Oncology market (30 INN) |
10,3 |
9,2 |
12% |
|
relevant market Other drugs (166 INN) |
61,0 |
58,9 |
3,5% |
"We are starting 2026 with strong operational results that confirm the sustainability of our chosen strategy for innovative development and commercialization of next-generation drugs. PROMOMED continues to demonstrate growth rates that are many times higher than the dynamics of the pharmaceutical market, and the drugs in our endocrinology portfolio have consolidated their leadership positions. In Q1 2026, PROMOMED's share in the retail market of GLP-1 class drugs exceeded 53% in monetary terms, and Tirzetta® became one of the key growth drivers of the entire commercial pharmaceutical market in Russia. Such a bright start to the year is a clear and clear signal from a healthy business to achieve our financial and operational goals in 2026, including further expanding our innovation portfolio, increasing shareholder value, and increasing the Company's investment attractiveness.
In the reporting period, we also continued to implement initiatives aimed at increasing the Company's shareholder value: we updated the dividend policy, recommended dividends at 46% of adjusted net income for 2025, increased the free float and launched a program to maintain stock liquidity. We are confident that the combination of strong operating results, leadership in strategic segments, and continued business growth creates a solid foundation for consistently increasing the Company's investment attractiveness."|
Показатели на отчетную дату |
31.03.26 |
31.12.25 |
Изм. |
|
|
|
Кол-во препаратов в портфеле, шт. |
370 |
364 |
6 шт. |
|
|
|
Кол-во сотрудников |
3 187 |
2 826 |
13% |
|
|
|
Кол-во сотрудников в R&D |
554 |
500 |
11% |
|
|
|
Регистрационные удостоверения по нозологиям на 31.03.26 |
|||||
|
Эндокринология |
23 |
||||
|
Онкология |
56 |
||||
|
Неврология |
66 |
||||
|
Антибиотики |
71 |
||||
|
Общая терапия |
112 |
||||
|
Противовирусные |
32 |
||||
|
Иммунология |
3 |
||||
|
Ветеринария |
5 |
||||
|
Орфанные |
2 |
||||
ЭНДОКРИНОЛОГИЯ
В сегменте Эндокринология выручка за 1 кв. 2026 года выросла на 196% г/г и составила 4,8 млрд руб., в первую очередь за счет ускоренного роста продаж препаратов для терапии ожирения и сахарного диабета 2 типа: Тирзетта®, Велгия®, Велгия® Эко, а также начала коммерциализации Семальтара®. Продажи Группы значительно обогнали темпы роста релевантного рынка (9 МНН), который в отчетном периоде вырос на 143%, до 20,2 млрд руб.
ПРОМОМЕД последовательно укрепляет позиции в одном из наиболее быстрорастущих сегментов фармацевтического рынка. По данным DSM Group, за 1 кв. 2026 года Группа стала лидером продаж на розничном рынке препаратов класса ГПП-1 в России с долей 53,6% в стоимостном выражении. Среди молекул в сегменте уже в марте в лидеры вышел тирзепатид с долей 51%.
• Тирзетта® (тирзепатид) — препарат нового поколения для терапии ожирения и сахарного диабета 2 типа. Лидерство препарата на российском рынке было отмечено ведущими аналитическими агентствами:
o По данным RNC Pharma Тирзетта® в 1 кв. 2026 года стала торговой маркой #1 среди всех лекарственных препаратов на розничном рынке России по объему продаж в стоимостном выражении. Доля Тирзетта® на розничном рынке лекарственных препаратов составила 1,14%, а продажи выросли в 89 раз г/г.
o По данным DSM Group Тирзетта® стала брендом #1 по объёму аптечных продаж уже в январе и удерживала лидерство на протяжении последующих двух месяцев. По итогам 1 кв. 2026 года доля препарата в коммерческом аптечном рынке лекарственных препаратов составила 1,25%.
В отчетном периоде ПРОМОМЕД продолжил развитие клинической программы Тирзетта® и запустил плацебо-контролируемое многоцентровое исследование эффективности и безопасности применения препарата для лечения ожирения и избыточнweight loss in adolescents aged 12 years and older. The study will involve 240 patients in 18 medical organizations in Russia.
• Semaltara®(semaglutide) is the first and currently the only semaglutide—based tablet drug in Russia for the treatment of type 2 diabetes mellitus and weight maintenance after completion of the course of injection therapy, commercialization of the drug started in Q1 2026. Semaltara® expands the range of modern PROMOMED solutions and is one of the drivers of further growth of the endocrinology portfolio. In Q1 2026, sales of the drug amounted to more than 400 million rubles.
• Velgia® and Velgia® Ivf(semaglutide) — semaglutide-based drugs specially developed for the treatment of obesity. Drug sales for Q1 2026 amounted to 858 million rubles, and according to the DSM Group, Velgia® reached the 10th line of the rating of medicines in the commercial pharmacy market with a market share of 0.55%. At the beginning of 2026, the Company increased the availability of starting dosages of Velgiya® and Velgiya® drugs. Ivf (0.25 mg and 0.5 mg), which expands the possibilities of therapy for patients.
ONCOLOGY
In the Oncology segment, revenue for Q1 2026 amounted to 0.7 billion rubles. compared to 1.2 billion rubles in Q1 2025. The relevant market (30 INN) showed an increase of 12% to 10.3 billion rubles, while, according to IQVIA, secondary sales of the Company's drugs increased by 84%.
- The decrease compared to the same period in 2025 is due to a change in the plan of primary shipments to suppliers that are tied to the timing of public procurement: in 2026, the key tenders for the company are concentrated in the second half of the year. The company also expects to accelerate sales in the Budget segment due to new drug launches in the second half of 2026. Significant sales, amounting to more than 300 million rubles, were shown by the antitumor drugs Avenium® Pro (launched at the end of 2025) and Vandetanib-Promomed (a domestic analogue of the drug Caprels® from Sanofi, launched in 2024).
- A registration clinical trial of the original monoclonal antibody conjugate, a last-generation drug for the treatment of breast cancer (LTBB14701), as well as a study of the pharmacokinetics and safety of the original drug for the treatment of non-small cell lung cancer (LTBB14601), has been launched. Both drugs are included in the pipeline of key launches.
OTHER DRUGS: GENERAL THERAPY, ORPHAN, ANTIVIRAL, NEUROLOGY, IMMUNOLOGY, ANTIBIOTICS AND OTHERS
In the Other drugs segment, revenue for Q1 2026 increased by 8.7% YoY to RUB 1.8 billion. The growth of the relevant market (166 INN) amounted to 3.5% to 61 billion rubles.
- Among antiviral drugs, Ambervine® Pulmo continues to show excellent results. In the reporting period, the Russian Ministry of Health approved a new indication for the use of the drug in the complex therapy of community-acquired pneumonia. The decision is based on the results of a multicenter, blind, randomized, comparative, placebo-controlled trial.
- Significant revenue growth in the segment was also shown by: Glutegris® (teduglutide) is an orphan drug developed in 2025 for the treatment of short bowel syndrome, a rare and severe disease, as well as having a high potential for the treatment of traumatic intestinal injury; Cladribine - PROMOMED is an effective and safe drug for the treatment of multiple sclerosis.
- In February 2026, the Ministry of Health expanded the indications for use Esperavir® is the first Russian drug based on molnupiravir, registered and successfully used in Russia for the treatment of COVID-19. According to the results of a clinical trial led by the Chief Internist of the Russian Federation, indications for the use of the drug for the treatment of influenza and acute respiratory viral infections (ARVI) were approved.
- Klobegen® - Pro is a drug for the treatment of orphan disease spinal muscular atrophy (SMA). In Q1 2026, phase IV of clinical trials was launched, the results of which will form the basis for new medical care algorithms, including the use of the drug in adults and children receiving other types of therapy.
CORPORATE EVENTS AND EVENTS AFTER THE REPORTING DATE
- PROMOMED is developing an export business: the key production site of the group is the Biochemist plant, which has successfully passed the audit of the Ministry of Health of the Republic of Uzbekistan and the UAE Medicines Authority, and received international GMP certificates that open the possibility of supplying PROMOMED drugs to the pharmaceutical market of Uzbekistan and the UAE. The list of planned drugs includes drugs from the Velgia® endocrinological portfolio. Ivf and Tirzetta®, as well as drugs for the treatment of cancer and infection control.
- The Company's Board of Directors recommended paying dividends in the amount of 8.00 rubles. per share, which corresponds to 46% of PROMOMED's adjusted net profit for 2025.
- A program to increase the liquidity of shares has been launched: ATON LLC has become the market maker for the Company's securities. The initiative is aimed at increasing the liquidity of securities and reducing volatility as part of a long-term shareholder value creation program.
The share of PROMOMED shares in free circulation increased from 6.7% to 8.5% due to the repayment of the Company's structural bonds. The bonds were repaid by transferring PROMOMED shares to investors, which reduced the Company's short-term debt by 1.6 billion rubles. The decision corresponds to the Company's medium-term goal of moving to the first quotation list.
About the Company
PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market. PROMOMED celebrated its 20th anniversary in 2025. The ordinary shares of PJSC Promomed are traded on the Moscow Stock Exchange (ticker "PRMD").
The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.
Contacts
|
For investors |
For the media |
This message and the information contained therein are not:
- an offer to purchase any securities,
- an invitation to make offers to purchase any securities,
- as part of such offers or invitations,
- advertising of securities in the Russian Federation or other jurisdictions,
- an offer to purchase medicines,
- advertising of medicines,
- by encouraging or recommending transactions,
- and is also not subject to interpretation as such.
Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.
Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.
The publication of this communication does not imply investment advice (in the meaning defined in the legislation of the Russian Federation (includingFor example, in Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.
Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page https://e-disclosure.ru/portal/company.aspx?id=38533.
The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.
The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.
The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
